摘要
目的:探讨雌激素诱导蛋白pS2的表达与乳腺癌临床参数和辅助三苯氧胺TAM治疗疗效的关系,明确pS2对辅助内分泌治疗的指导地位。方法:采用免疫组化S蛳P法检测81例ER阳性原发乳腺癌的石蜡切片pS2的表达, 统计学分析其与预后的关系。结果:原发乳腺癌pS2的阳性表达率为66.7 %,其表达与手术年龄(P=0.037)、月经状态(P=0.016)、肿瘤大小(P=0.029)、PR表达情况(P<0.001)密切相关,年龄小于50岁、绝经前、小肿瘤、PR阳性的患者pS2阳性率高。单因素分析和多因素分析均表明pS2是预测OS的独立预后因子。同时pS2对DFS也具有独立预后价值(P=0.023)。结论:pS2是预测ER阳性乳腺癌患者辅助内分泌治疗疗效的独立指标。
Objective: To investigate the expression of estrogen- induced protein pS2 in breast cancer and it's relation to the clinical manifestations and the response to adjuvant tamoxifen therapy. Methods: Immunostaining for pS2 was performed on 81 paraffin- embedded specimens of ER+ primary breast cancer patients. Results: Positive expression rate of pS2 in primary breast cancer was 66.7 %. Expression of pS2 was positively correlated with age(P=0.037),menopausal status(P=0.016),tumor size(P=0.029)and PR(P<0.001). pS2 positivity was more frequent in young ,postmenopausal and PR+ patients as well as small tumors. Both univariate and multivariate analysis demonstrated pS2 had independent influence on OS. pS2 could also provide independent information for DFS(P=0.023). Conclusion: pS2 status can be used as a parameter additional to ER for better refinement of prediction of response to adjuvant tamoxifen therapy.
出处
《肿瘤研究与临床》
CAS
2004年第2期97-99,共3页
Cancer Research and Clinic
